{
    "clinical_study": {
        "@rank": "143009", 
        "acronym": "RECAM", 
        "arm_group": {
            "arm_group_label": "peripheral artery disease", 
            "description": "de novo stenotic lesions in superficial femoral artery"
        }, 
        "brief_summary": {
            "textblock": "Non-randomized multicenter post-market study to confirm the long-term safety and\n      effectiveness of the CE-approved Camouflage-coated self-expandable RESISTANT Camouflage\n      stent system for revascularization of de novo stenotic lesions in the superficial femoral\n      artery in 100 compliant patients suitable for stent angioplasty.\n\n      The CE-approved device will be used according to its intended use. Beyond the standard of\n      care no further interventions are scheduled. Therefore, this trial is subject to the\n      exception to the rule \u00a723b of the German Medical Device Act (MPG), which includes the\n      national implementation of EC directive 93/42/EEC."
        }, 
        "brief_title": "Multicentric Non-randomized Investigation of RESISTANT Camouflage Stent-system", 
        "completion_date": {
            "#text": "February 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Peripheral Artery Disease", 
        "condition_browse": {
            "mesh_term": "Peripheral Arterial Disease"
        }, 
        "detailed_description": {
            "textblock": "The aim of this non-randomized post-market clinical follow-up study is to confirm long-term\n      safety and effectiveness of the CE-approved Camouflage-coated self expandable RESISTANT\n      Camouflage stent system for revascularization of de novo stenotic lesions in superficial\n      femoral artery in 120 compliant patients suitable for stent angioplasty. The primary end\n      point is the target lesion revascularization after 12 months. Further follow-ups are\n      scheduled at discharge, 30 days, 6 and 24 months."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age of 18 to 95 years\n\n          -  Male or non-pregnant female\n\n          -  De novo lesions>70% or occlusions in the SFA (Superficial Femoral Artery) arteries\n             suitable for stent angioplasty\n\n          -  Max. 1 lesion within each leg should be treated as study lesions\n\n          -  Lesions length range from \u22653 cm to \u226418 cm\n\n          -  A patent inflow artery free from significant lesions (>50 % stenosis) as confirmed by\n             angiography. Treatment of target lesion acceptable after successful treatment of\n             inflow artery lesions.\n\n          -  Reference vessel diameter \u22653 mm and \u2264 7 mm\n\n          -  Successful guide wire passage of the lesion\n\n          -  Symptomatic peripheral artery disease (Rutherford stage 2 to 5)\n\n          -  Patient is willing to provide informed consent and comply with the required follow-up\n             visits, testing schedule, and medication regimen\n\n        Exclusion Criteria:\n\n          -  Patients for whom an anti-platelet therapy, anticoagulants or thrombolytics are\n             contraindicated\n\n          -  Patients presenting a lasting intraluminal thrombosis at the lesion after a\n             thrombolytic therapy\n\n          -  Perforation at the location of the angioplasty characterized by secretion of the\n             contrast medium\n\n          -  Aneurysm of the artery to be treated\n\n          -  All common contraindications for a PTA (Percutaneous Transluminal Angioplasty)\n\n          -  Contraindications for stent angioplasty\n\n          -  Hypersensitivity/allergy to nickel-titanium\n\n          -  Hypersensitivity/allergy to any of the components of the delivery & dilation system\n\n          -  Severe renal insufficiency (creatinine>2.0 mg/dL or glomerular filtration rate < 60\n             ml/min/1.73)\n\n          -  Uncorrected bleeding disorder\n\n          -  Major gastrointestinal bleeding within the last 6 months.\n\n          -  Ipsilateral intervention other than target vessel\n\n          -  Untreated ipsilateral iliac artery stenosis >70 %\n\n          -  Previous stenting or prior surgery of the SFA\n\n          -  In-stent restenosis\n\n          -  Acute myocardial infarct within 72 h\n\n          -  Less than one patent crural artery\n\n          -  Popliteal stenosis > 70 %\n\n          -  Manifest hyperthyroidism\n\n          -  Acute onset of symptoms\n\n          -  Leg-threatening ischemia\n\n          -  Multimorbid patient with poor general condition\n\n          -  Pregnant woman or becoming pregnant in < 2 yrs\n\n          -  Living more than 100 km apart from the study center\n\n          -  Patient actively participating in another investigational device or drug study\n\n          -  History of hemorrhagic stroke within 3 months\n\n          -  Previous or planned surgical or interventional procedure within 30 days of the\n             procedure\n\n          -  Acute or sub-acute thrombus in target vessel\n\n          -  Acute vessel occlusion or sudden symptom onset\n\n          -  Lesions in target area requiring atherectomy (or ablative devices), cutting balloons,\n             cryoplasty balloons, or any other advanced device to facilitate angioplasty balloon\n             or stent delivery\n\n          -  Use of adjunctive therapies (i.e. laser, atherectomy, cryoplasty, scoring/cutting\n             balloon, etc.)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "95 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "patients with de novo stenotic lesions in the superficial femoral artery"
            }
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02011984", 
            "org_study_id": "recam2013_eucatech", 
            "secondary_id": "ECT024ResiCSfaRegV10"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "February 14, 2014", 
        "location": [
            {
                "contact": {
                    "email": "wulf.euringer@uniklinik-freiburg.de", 
                    "last_name": "Wulf Euringer, M.D.", 
                    "phone": "0049 761 270", 
                    "phone_ext": "38580"
                }, 
                "facility": {
                    "address": {
                        "city": "Freiburg", 
                        "country": "Germany", 
                        "state": "Baden W\u00fcrttemberg", 
                        "zip": "79095"
                    }, 
                    "name": "Uniklinikum Freiburg, Abteilung R\u00f6ntgendiagnostik"
                }, 
                "investigator": {
                    "last_name": "Wulf Euringer, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "burbelko@med.uni-marburg.de", 
                    "last_name": "Mykhaylo Burbelko, M.D.", 
                    "phone": "0049 6421 58", 
                    "phone_ext": "65912"
                }, 
                "facility": {
                    "address": {
                        "city": "Marburg", 
                        "country": "Germany", 
                        "state": "Hessen", 
                        "zip": "35043"
                    }, 
                    "name": "Uniklinikum Gie\u00dfen und Marburg, Diagnostische und Interventionelle Radiologie"
                }, 
                "investigator": {
                    "last_name": "Mykhaylo Burbelko, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "kolvenbach@vkkd-kliniken.de", 
                    "last_name": "Ralf Kolvenbach, Prof.", 
                    "phone": "0049 211 9043", 
                    "phone_ext": "301"
                }, 
                "facility": {
                    "address": {
                        "city": "D\u00fcsseldorf", 
                        "country": "Germany", 
                        "state": "Nordrhein - Westfalen", 
                        "zip": "40472"
                    }, 
                    "name": "Augusta-Krankenhaus, Klinik f\u00fcr Gef\u00e4\u00dfchrirugie"
                }, 
                "investigator": {
                    "last_name": "Ralf Kolvenbach, Prof.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "irad@hbk-zwickau.de", 
                    "last_name": "J\u00f6rg Thalwitzer, M.D.", 
                    "phone": "0049 375", 
                    "phone_ext": "-4854/-4855"
                }, 
                "facility": {
                    "address": {
                        "city": "Zwickau", 
                        "country": "Germany", 
                        "state": "Sachsen", 
                        "zip": "08060"
                    }, 
                    "name": "Heinrich Braun Klinikum Zwickau, Radiologie und Neuroradiologie"
                }, 
                "investigator": {
                    "last_name": "J\u00f6rg Thalwitzer, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "segreteria@centroendovascolare.it", 
                    "last_name": "Cesare Massa Saluzzo, M.D.", 
                    "phone": "0039 3349419996"
                }, 
                "facility": {
                    "address": {
                        "city": "Pavia", 
                        "country": "Italy", 
                        "state": "Lombardy", 
                        "zip": "27100"
                    }, 
                    "name": "CCP - Istituto di Cura \"Citt\u00e0 di Pavia\""
                }, 
                "investigator": {
                    "last_name": "Cesare Massa Saluzzo, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Germany", 
                "Italy"
            ]
        }, 
        "number_of_groups": "1", 
        "official_title": "Multicentric Non-randomized Investigation of RESISTANT Camouflage Stent-system in Peripheral Superficial Femoral Arteries", 
        "overall_contact": {
            "email": "c.marx@clinical-evaluation.com", 
            "last_name": "Claudia Marx, MD", 
            "phone": "00497621167333", 
            "phone_ext": "20"
        }, 
        "overall_official": {
            "affiliation": "Eucatech AG", 
            "last_name": "Michael Giese, Phd", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: Ethics Commission", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Target lesion revascularization (TLR) rate", 
            "measure": "Target lesion revascularization (TLR)", 
            "safety_issue": "Yes", 
            "time_frame": "12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02011984"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Adverse Event rate", 
                "measure": "Adverse Event", 
                "safety_issue": "Yes", 
                "time_frame": "24 hours"
            }, 
            {
                "description": "Adverse Event rate", 
                "measure": "Adverse Event", 
                "safety_issue": "Yes", 
                "time_frame": "48 hours"
            }, 
            {
                "description": "Adverse Event rate", 
                "measure": "Adverse Event", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Adverse Event rate", 
                "measure": "Adverse Event", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Adverse Event rate", 
                "measure": "Adverse Event", 
                "safety_issue": "Yes", 
                "time_frame": "24 months"
            }, 
            {
                "description": "The ability to successfully complete stent angioplasty and achieve a residual diameter stenosis of \u2264 30 %.", 
                "measure": "Technical success", 
                "safety_issue": "No", 
                "time_frame": "24 hours"
            }, 
            {
                "description": "Procedural success rate", 
                "measure": "Procedural success", 
                "safety_issue": "No", 
                "time_frame": "24 hours"
            }, 
            {
                "description": "Change from baseline in Walking Impairment Questionnaire scores", 
                "measure": "Walking Impairment Questionnaire", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Change from baseline in Walking Impairment Questionnaire scores", 
                "measure": "Walking Impairment Questionnaire", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Change from baseline in Rutherford stage", 
                "measure": "Rutherford classification", 
                "safety_issue": "No", 
                "time_frame": "48 hours"
            }, 
            {
                "description": "Change from baseline in Rutherford stage", 
                "measure": "Rutherford classification", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Change from baseline in Rutherford stage", 
                "measure": "Rutherford classification", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Change from baseline in Rutherford stage", 
                "measure": "Rutherford classification", 
                "safety_issue": "No", 
                "time_frame": "24 months"
            }, 
            {
                "description": "Change from baseline in health-related quality of life (SF-36 questionnaire scores)", 
                "measure": "Health-related quality of life (SF-36 questionnaire)", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Percentage of lesions that reach endpoint without TLR or with stenosis < 50% on duplex ultrasonography (PSVR (Peak Systolic Velocity Ratio) < 2.4)", 
                "measure": "Primary patency", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Percentage of lesions that reach endpoint without TLR or with stenosis < 50% on duplex ultrasonography (PSVR (Peak Systolic Velocity Ratio) < 2.4)", 
                "measure": "Primary patency", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Percentage of lesions that reach endpoint without TLR or with stenosis < 50% on duplex ultrasonography (PSVR (Peak Systolic Velocity Ratio) < 2.4)", 
                "measure": "Primary patency", 
                "safety_issue": "No", 
                "time_frame": "24 months"
            }, 
            {
                "description": "Change from baseline in Ankle brachial index (ABI)", 
                "measure": "Ankle brachial index (ABI)", 
                "safety_issue": "No", 
                "time_frame": "48 hours"
            }, 
            {
                "description": "Change from baseline in Ankle brachial index (ABI)", 
                "measure": "Ankle brachial index (ABI)", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Change from baseline in Ankle brachial index (ABI)", 
                "measure": "Ankle brachial index (ABI)", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Change from baseline in Ankle brachial index (ABI)", 
                "measure": "Ankle brachial index (ABI)", 
                "safety_issue": "No", 
                "time_frame": "24 months"
            }
        ], 
        "source": "Eucatech AG", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Eucatech AG", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational [Patient Registry]", 
        "target_duration": "2 Years", 
        "verification_date": "February 2014"
    }
}